Continuous Glucose Monitor (CGM) Interpretation by Decade of Life

CGM here refers to the device class generically, including systems such as Dexcom G7 and Abbott FreeStyle Libre 3, used either for managing diagnosed diabetes or, off-label from a diagnostic standpoint, for glucose pattern monitoring in people without diabetes. A CGM is not a diagnostic test for diabetes or prediabetes; the diagnostic standard remains fasting plasma glucose, oral glucose tolerance testing, or HbA1c.

A CGM report becomes clinically meaningful only when read against an age- and risk-adjusted target, not a single universal range. The American Diabetes Association's 2024 Standards of Care set a time-in-range target of more than 70% (70-180 mg/dL) for most adults with diagnosed diabetes, but relax that target to as low as 50% for older adults with high frailty or multiple comorbidities, prioritizing avoidance of hypoglycemia over tight control. Tighter non-diabetic optimization ranges used by some clinicians, such as 70-140 mg/dL, reflect clinical practice patterns and observational associations rather than an ADA-endorsed diagnostic or treatment target, and their comparative outcome benefit has not been established in randomized trials.

What a CGM report actually shows

A CGM produces an Ambulatory Glucose Profile (AGP): a summary of time in range, time below range, time above range, mean glucose, and glucose variability across the wear period. It captures postprandial spikes and nocturnal patterns that a single fasting blood draw cannot. Because insulin sensitivity, counter-regulatory hormone responses, and gastric emptying speed all shift with age, the same raw number can mean different things in a 28-year-old and a 74-year-old.

The core AGP metrics, as they are commonly reported by CGM software (Dexcom Clarity, LibreView, and similar platforms):

• Time in Range (TIR): percent of readings 70-180 mg/dL for people with diabetes, or a tighter 70-140 mg/dL window used in non-diabetic optimization contexts.
• Time Below Range (TBR): split into Level 1 (54-69 mg/dL) and Level 2 (below 54 mg/dL). This is the primary safety metric for anyone on insulin or a sulfonylurea.
• Time Above Range (TAR): split into Level 1 (181-250 mg/dL) and Level 2 (above 250 mg/dL).
• Glucose Management Indicator (GMI): a formula-derived estimate of HbA1c from mean sensor glucose. GMI can diverge meaningfully from a lab HbA1c in people with hemoglobin variants or altered red blood cell turnover, so it should be treated as a trend indicator, not a lab-equivalent result.

An international consensus effort involving major diabetes organizations has proposed standardized AGP targets and repeatedly emphasized that targets should be individualized by age, hypoglycemia risk, and comorbidity rather than applied uniformly. Readers who want the primary consensus document itself should look it up directly in Diabetes Care rather than relying on a secondhand summary, since the exact numeric thresholds in various derivative articles are inconsistently reported.

Why decade of life is a proxy, not a rule

Two things change with age on population averages: insulin sensitivity tends to decline, widening postprandial excursions and raising fasting glucose modestly even without a diabetes diagnosis; and the physiological buffer against hypoglycemia narrows, because counter-regulatory hormone responses weaken and cardiac conduction risk during a low rises. Both trends are well established in general endocrinology, but neither trend applies uniformly. A very active, lean 70-year-old and a sedentary, multi-comorbid 55-year-old can have inverted risk profiles relative to their decade averages. That is the reason this article, after walking through decade-level patterns, ends with a risk-factor-based decision framework rather than a strict age lookup table.

20s and 30s: establishing a baseline

Healthy adults in their 20s and early 30s typically show the tightest CGM profiles of any age group: high time in a narrow range, brief postprandial excursions, and low variability. Persistent mean glucose that runs high for this age group, or a GMI approaching the ADA's prediabetes HbA1c threshold of 5.7%, is a reasonable prompt for a fasting glucose and fasting insulin check, since this can be an early sign of insulin resistance, polycystic ovary syndrome, or an emerging beta-cell issue. This is a clinical judgment call, not a validated CGM diagnostic threshold; the ADA does not currently endorse CGM as a standalone diagnostic tool for prediabetes.

A coefficient of variation persistently above the commonly cited 36% threshold in someone in this age range without diabetes is unusual and worth a dietary and eating-pattern review, since it can reflect reactive hypoglycemia or a pattern of prolonged fasting followed by large carbohydrate loads.

40s: hormonal transitions widen the picture

Estrogen supports insulin sensitivity through multiple pathways, and declining estrogen during perimenopause is generally associated with increased central adiposity and reduced glucose-handling efficiency. It is biologically plausible, and consistent with general endocrine literature, that perimenopausal women see wider CGM excursions than pre-menopausal women of similar body composition, but the exact magnitude reported in any single small study should not be treated as a fixed number without checking the primary paper. Menstrual cycle phase also matters practically: a 14-day CGM wear that captures only the luteal phase, when glucose tends to run somewhat higher, will not represent an average pattern.

In men, declining testosterone is associated with higher HOMA-IR and wider glucose swings in the general literature on hypogonadism and metabolic syndrome, though the size of any glucose improvement from testosterone replacement specifically, and whether it is clinically meaningful, requires review of the primary trial literature rather than a single cited effect size.

50s: prediabetes surveillance years

A substantial share of U.S. adults have prediabetes, and most are undiagnosed, according to CDC national diabetes surveillance data; readers should check the current CDC report for the up-to-date prevalence figure rather than rely on a fixed percentage, since surveillance estimates are updated periodically (CDC diabetes data and statistics, accessed 2025). The ADA's 2024 Standards of Care recommend diabetes and prediabetes screening in adults 35 and older, and in younger adults with risk factors. CGM is not listed by the ADA as a primary screening or diagnostic tool for prediabetes; its role here is supported by expert clinical opinion and observational research suggesting CGM can pick up postprandial dysregulation before HbA1c rises, not by an ADA diagnostic endorsement.

A 2025 expert-group discussion on integrating CGM into type 2 diabetes care describes CGM's expanding clinical role in monitoring glycemic patterns beyond diagnosis, which is consistent with this surveillance use, though that discussion is centered on people with an established type 2 diabetes diagnosis rather than prediabetes screening specifically (Enhancing Type 2 Diabetes Care With CGM Integration, 2025).

60s: balancing tighter control against hypoglycemia harm

A well-known large randomized trial in adults with established type 2 diabetes and high cardiovascular risk (average age in the early 60s) found that targeting near-normal HbA1c increased mortality compared with standard glycemic targets, a finding generally attributed at least in part to hypoglycemia and its cardiac effects. This trial used HbA1c rather than CGM-derived time in range, so its lessons map onto CGM's time-below-range metric by extension rather than by direct measurement. The practical translation used in current ADA guidance is that older adults with multiple comorbidities or elevated hypoglycemia risk should target a time-in-range goal in the 50-70% band (70-180 mg/dL) rather than the stricter 70% target used in healthier adults, with the time-below-range ceiling below 70 mg/dL taking priority.

Anyone using a CGM alarm for hypoglycemia protection should treat a Level 2 low (below 54 mg/dL), especially with symptoms such as confusion, sweating, or palpitations, as a reason to treat immediately per their care plan and to contact their prescriber; recurrent Level 2 lows warrant an urgent medication review rather than waiting for the next routine visit.

70s and beyond: frailty changes the goal

People 70 and older show the widest spread of physiologic variation of any age group covered here. The ADA's frailty-stratified framework generally groups older adults into healthier, intermediate/complex, and high-frailty categories, with looser glycemic targets and a shift toward hypoglycemia prevention as the priority as frailty increases. The Endocrine Society's clinical practice guideline on diabetes in older adults reflects the same principle: glycemic targets should follow health status and patient preference rather than age alone.

Older adults aged 75 and above taking sulfonylureas experience notably elevated severe hypoglycemia rates compared to younger adults on these medications, based on hospitalization and emergency department data. However, specific risk ratios from individual retrospective studies warrant verification in the original source before citing as definitive figures. For older adults on insulin or sulfonylureas, CGM alerts configured to trigger before hypoglycemic symptoms develop represent a practical harm-reduction strategy. Claims about specific reductions in emergency department utilization attributable to CGM use should be confirmed in the original research before being cited as percentages.

Glucose variability across every decade

Coefficient of variation (CV), calculated as the standard deviation of glucose divided by the mean and expressed as a percentage, is commonly used as a marker of how well the body buffers glucose flux, independent of the average glucose level itself. A CV consistently above roughly 36% is a widely cited flag, though it functions better as a prompt for a closer look than as a diagnostic cutoff. What tends to drive high CV differs by life stage: irregular meal timing, alcohol, and aggressive intermittent fasting in the 20s-30s; hormonal flux and shift work in the 40s-50s; and medication effects (sulfonylureas, insulin), gastroparesis, and erratic meal patterns tied to social isolation in the 60s-70s.

Visit-to-visit and day-to-day glucose variability has been linked to adverse cardiovascular outcomes in some large diabetes trial populations independent of mean glucose, but the size of that association and whether it generalizes to non-diabetic CGM users has not been established, and readers should not treat a CV number as an independently validated risk score outside a diabetes-management context.

How long to wear a CGM, and which device

International consensus guidance generally recommends a minimum of 14 days of wear with substantial data capture (commonly cited as roughly 70%) to produce a representative AGP report; shorter wear periods miss weekend behavior shifts and overnight patterns. For people managing diabetes with insulin, continuous or near-continuous wear is standard practice; for non-diabetic optimization users, repeat 14-day cycles every few months is a common but not formally standardized protocol.

Current-generation sensors (Dexcom G7, Abbott FreeStyle Libre 3) are FDA-cleared for specific uses that vary by model and have changed over time, including for some models a clearance supporting insulin dosing decisions. Exact clearance status, indicated population, and accuracy specifications (commonly summarized as Mean Absolute Relative Difference, or MARD) should be checked against current FDA labeling rather than assumed from a prior year's device documentation, since labeling and clearances are updated (verify at fda.gov). Sensor accuracy is understood to degrade somewhat during rapid glucose change, such as right after a meal or after exercise, which is exactly when older adults on insulin or sulfonylureas face the highest hypoglycemia risk from a treatment decision based on a single reading. A person should not adjust insulin or medication dosing from a CGM reading during a period of rapid change without following their prescriber's specific instructions.

The longevity-medicine practice pattern, and its evidence limits

A growing group of clinicians working in longevity and metabolic health apply a tighter CGM target range (70-140 mg/dL rather than 70-180 mg/dL) even for people without diabetes, reasoning from epidemiological associations between fasting glucose in the high-normal range and elevated cardiovascular risk. This is an observational association, not a randomized-trial demonstration that lowering glucose within this non-diabetic range reduces cardiovascular events. Duration of elevation likely matters more than a single peak value: a brief rise to 155 mg/dL after a mixed meal that returns to baseline within an hour is physiologically different from glucose sustained around 145 mg/dL for most of the waking day, but the precise duration-risk relationship has not been established through controlled trials in non-diabetic CGM users.

A qualitative synthesis of patient experience with CGM in type 1 diabetes found that continuous monitoring can function either as a reassuring tool or as a source of anxiety and hypervigilance, depending on the person and context, which is a relevant caution for anyone, at any age, starting non-diabetic optimization monitoring expecting only benefit (Best friend or spy: a qualitative meta-synthesis, 2018; this synthesis was conducted in people with type 1 diabetes, and its direct applicability to non-diabetic optimization users has not been established).

What is established, what is plausible, and what is not established

Established: CGM measures interstitial glucose continuously and reveals postprandial and nocturnal patterns invisible to fasting labs. The ADA sets a time-in-range target above 70% (70-180 mg/dL) for most people with diagnosed diabetes, with an explicitly looser target for high-frailty older adults, prioritizing hypoglycemia avoidance. Insulin sensitivity generally declines and hypoglycemia risk generally rises with age on a population level.

Plausible but unproven: That tighter non-diabetic optimization ranges (70-140 mg/dL) meaningfully reduce long-term cardiovascular or metabolic disease risk compared with standard reference ranges. That perimenopausal hormone shifts produce a specific, reproducible magnitude of CGM excursion widening. That CGM adoption specifically reduces hypoglycemia-related emergency visits in older adults by any particular percentage; the direction is plausible from device function, but a precise effect size requires checking the primary study.

Not established: CGM as a standalone diagnostic tool for prediabetes or diabetes. A validated, age-specific numeric glucose target endorsed by a regulatory body or major guideline body for non-diabetic adults; the 70-140 mg/dL range in wide clinical use is a practice pattern, not a guideline target.

Decision framework: which CGM target tier applies to you

Use this to translate a decade-based default into an individual target, since risk factors override age.

Step 1: Do you have a diagnosed diabetes condition (type 1 or type 2)?

• No, and no known prediabetes: your relevant range is a general reference range, not a treatment target. Decade patterns above are descriptive, not prescriptive. Skip to Step 3 only if you are pursuing CGM for optimization purposes and want to understand what a clinician might flag.
• Yes, or diagnosed prediabetes: continue to Step 2.

Step 2: Do any of the following apply to you?

• Age 65 or older, or frailty/multiple chronic conditions at any age
• Current use of insulin or a sulfonylurea
• Chronic kidney disease, advanced liver disease, or a history of severe or unrecognized hypoglycemia
• Cognitive impairment that could delay recognizing or treating a low
• History of falls or a cardiac conduction abnormality

If none apply: standard ADA target for diagnosed diabetes generally applies, TIR above 70% (70-180 mg/dL), time below 70 mg/dL under roughly 4%, time below 54 mg/dL under roughly 1%. This is a general guideline default; your prescriber sets your individual target.

If one or more apply: you likely fall into the ADA's intermediate or high-frailty category, where TIR targets loosen to roughly 50-70% and the priority shifts to keeping time below range low rather than maximizing time in the standard range. This is a discussion to have explicitly with your prescriber, not a self-adjustment.

Step 3: Regardless of category, treat these as reasons to contact your care team promptly rather than waiting for a routine visit:

• Time below 54 mg/dL rising above roughly 1% of readings, especially with symptoms
• A new pattern of overnight lows
• Sustained high readings alongside symptoms of hyperglycemia (excessive thirst, frequent urination, unexplained fatigue) or any ketone concern in someone with type 1 diabetes
• A CGM reading that seems physiologically implausible during rapid symptom onset (dizziness, confusion, sweating): confirm with a fingerstick rather than relying solely on the sensor value during rapid change

This framework describes how to categorize risk and when to escalate. It does not set an individual numeric target or dosing instruction; those require a clinician who knows the full medical history.